Key Market Players Profiled include Illumina, Qiagen, PerkinElmer, F. Hoffmann-La Roche, Thermo Fisher Scientific, Natera, Bio-Rad Laboratories, Adaptive Biotechnologies, Sysmex, Integrated DNA ...

At the American Society of Hematology annual meeting, a roundtable discussion highlighted the evolving role of minimal residual disease (MRD) as a treatment endpoint in multiple myeloma, exploring its ...

Edgardo S. Santos, MD, FACP, FASCO, highlighted how liquid biopsies are transforming lung cancer care by enabling faster, ...

Practice-changing studies in both frontline CLL and relapsed/refractory disease, presented at ASH 2024, are discussed by Dr Jennifer Woyach.

Johnson & Johnson “announced new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI significantly increased minimal residual disease, MRD, negativity rates in ...

The decision greenlights a new biomarker endpoint, minimal residual disease, for accelerated drug approval in multiple myeloma, and researchers say it could cut a decade off the drug development ...

Renovaro Inc. announces funding approval for LUMINA, a platform detecting minimal residual disease in lung cancer using multi-omics and AI. Renovaro Inc. announced that its subsidiary ...

Dr John Leonard shares key updates on DLBCL at ASH 2024, including long-term POLARIX trial data, ctDNA insights, and real-world results for polatuzumab, liso-cel, and bispecifics after CAR-T failure.

Opens in a new tab or window SAN DIEGO -- Patients with mantle cell lymphoma (MCL) and undetectable minimal residual disease (uMRD) after induction therapy did not live longer if they underwent ...

Adaptive Biotechnologies' management is scheduled to present on Tuesday, January 14th at 5:15 p.m. Pacific Time / 8:15 p.m.

Saad Z. Usmani, MD, MBA, FACP, discusses how the MajesTEC-5 study, presented at ASH 2024, demonstrates the potential of teclistamab in combination with standard therapy in the frontline setting, ...